Two hormones. One clinically coherent plan.
A compounded estrogen and progesterone preparation built around the clinical reason both hormones may belong in one plan.
About 10 minutes. No charge unless your clinician approves.
Convenience only counts if the medicine still makes sense.
This preparation combines Biest, a 50:50 blend of estriol and estradiol, with progesterone in one topical cream. The appeal is obvious: one measured application instead of managing two separate pieces of a hormone plan.
The medical judgment is less simple, and that is the important part.
For a woman with a uterus using systemic estrogen, a progestogen has a defined role in protecting the uterine lining. A combined compounded cream gives your clinician one format for prescribing both hormones when that approach fits your case.
A combined cream is a format choice inside a larger treatment decision, useful when your clinician can explain exactly why both hormones belong together in your individual prescription.
Estrogen carries the symptom-treatment role, progesterone carries uterine protection where applicable, and one compounded format can simplify a plan that would otherwise require separate products.
Read the evidence →For the patient who wants fewer moving parts without fewer safeguards.
The Consolidator
Two parts of the plan in one daily application can make the routine simpler. The simplification is useful only if your clinician is comfortable with the combined format medically.
Already on Tailored Estrogen
You have a uterus and a compounded estrogen plan already under review. Progesterone is not a cosmetic add-on to that plan. How it is delivered deserves its own clinical decision.
The Informed Skeptic
You have heard enough “bioidentical” marketing to know customization is often oversold. You want a clinician who can tell you when compounding helps, when separate components are better, and when an FDA-approved option makes more sense.
Compounded Biest 50:50 with Progesterone is not an FDA-approved drug product, and compounded combinations have not been shown to be safer or more effective than FDA-approved hormone therapy. A licensed provider determines whether a combined preparation suits your history, or whether separate components serve you better.
This might not be the right fit if:
- History of breast cancer or another estrogen-dependent malignancy
- Unexplained vaginal bleeding
- History of blood clots, stroke, or heart attack
- Active liver disease
- Pregnancy or planned pregnancy ## Updated copy: GLP-1 and Metabolic
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Biest 50:50 with Progesterone, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Bi-estrogen, estriol and estradiol 50:50, with progesterone in one topical cream
- Compounded to your clinician’s specification by a licensed 503A pharmacy
- Applied as directed by your clinician
- Progesterone strategy reviewed specifically for endometrial protection when you have a uterus
- Treatment format reviewed and adjusted through your ongoing provider relationship
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
More in Hormones & Vitality.
Estradiol Gel
Menopause symptoms should not set the pace.
Prescription estradiol gel delivers systemic estrogen through the skin in an adjustable daily format.
Estradiol Patches
Twice weekly. Steady by design.
Prescription estradiol patches provide steady transdermal delivery with a twice-weekly change schedule.
Estradiol Tablet
A familiar form, backed by serious hormone care.
Prescription oral estradiol puts established hormone therapy into a familiar, straightforward daily form.
What the research shows
The National Academies found insufficient evidence to support compounded hormone therapy for menopause symptoms.
The detail
The question has been reviewed at the highest level available. At the FDA’s request, the National Academies of Sciences, Engineering, and Medicine convened a committee that reviewed the uses of compounded bioidentical hormone therapy and the evidence behind its marketing claims, with a prioritized focus that included estradiol, estriol and progesterone. Its 2020 consensus report concluded, in its own words, that given the paucity of data on the safety and effectiveness of compounded bioidentical hormone therapy there is insufficient evidence to support its overall clinical utility as a treatment for menopause symptoms, and its first recommendation is that prescribers restrict such preparations to a documented allergy to an ingredient of an FDA-approved product or a documented need for a different dosage form.1
The pooled trials’ only positive efficacy finding was vaginal androgen, not an estrogen or progesterone cream.
The detail
The most recent systematic review and meta-analysis of the field pooled 29 randomized controlled trials reported in 40 articles, covering 1,808 perimenopausal and postmenopausal women, comparing compounded preparations with placebo or with FDA-approved products. It found no adverse change in lipid profile or glucose metabolism with compounded androgen, no change in endometrial thickness and no serious adverse events in the included trials, and its single positive efficacy finding was for compounded vaginal androgen in vaginal atrophy symptoms, not for a compounded estrogen or progesterone cream.2
Oral micronized progesterone held endometrial hyperplasia to 6 percent against 64 percent on estrogen alone.
The detail
Endometrial protection has been demonstrated for oral micronized progesterone, at a defined oral dose. In a randomized, double-blind trial, 358 postmenopausal women with an intact uterus were treated for up to 36 months with oral micronized progesterone 200 mg a day for 12 days of each 28-day cycle plus conjugated estrogens 0.625 mg a day, conjugated estrogens alone, or placebo. Endometrial hyperplasia occurred in 6 percent of the combination group against 64 percent on estrogen alone and 3 percent on placebo. The approved indication is worded to match that route and regimen: prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens tablets, taken as a single daily dose at bedtime.3
In PEPI, every estrogen plus progestin regimen matched placebo on hyperplasia; estrogen alone did not.
The detail
The Postmenopausal Estrogen/Progestin Interventions trial found the same effect independently. Over three years in 596 postmenopausal women aged 45 to 64, randomized and double-masked, women on estrogen alone developed simple hyperplasia in 27.7 percent of cases, complex hyperplasia in 22.7 percent and atypical hyperplasia in 11.8 percent, against 0.8 percent, 0.8 percent and 0 percent on placebo, p less than 0.001, while all three estrogen plus progestin regimens, including cyclic oral micronized progesterone 200 mg a day, matched placebo, p equals 0.16.4
What it does not show
No randomized trial has tested this preparation as sold.
The detail
No randomized trial has tested this preparation as sold. There is no controlled trial of a combined compounded cream containing 50:50 estriol and estradiol with progesterone, so there is no efficacy figure, no dose-response curve and no safety database that belongs to this specific formulation, and the National Academies committee that reviewed the whole field concluded there is insufficient evidence to support routine clinical use of compounded bioidentical hormone therapy.1
Progesterone cream did not change the endometrium, and uterine protection is not established.
The detail
The endometrial protection question is the specific problem with a combined cream, and what has been measured points the other way. In a study of 27 postmenopausal women on continuous transdermal estrogen given a progesterone cream delivering 16, 32 or 64 mg daily on days 15 to 28 of each cycle, physiological estradiol levels were achieved but progesterone levels were insufficient to induce any detectable change in the endometrium, and salivary progesterone was too variable to guide therapy. A review of percutaneous progesterone reports that the serum levels achieved with creams are the central concern precisely because they are too low to produce a secretory endometrial effect, and that the question has to be settled by endometrial histology rather than by blood or saliva levels. Neither of those establishes that a compounded cream protects the uterine lining.56
The 6 versus 64 percent result belongs to oral progesterone, not to a cream.
The detail
The evidence that does exist belongs to other routes and other products. The 6 percent versus 64 percent hyperplasia result was produced by 200 mg of oral micronized progesterone taken at bedtime for 12 days per 28-day cycle alongside oral conjugated estrogens; it is a result about that regimen. The randomized evidence behind estradiol comes from specific FDA-approved gels, patches, tablets and vaginal products at defined strengths. A compounded combined cream is not any of those, and compounded preparations are not reviewed by the FDA for safety, effectiveness or quality.347
There are no FDA-approved drugs containing estriol, and the class risks remain unassessed.
The detail
One component has no approved product at all, and the class safety questions are unanswered. The FDA states that there are no FDA-approved drugs containing estriol, that marketed drugs containing estriol are compounded drugs which are not FDA-approved, and that it does not have evidence that drugs containing estriol are safe and effective or are safer forms of estrogen. The meta-analysis of compounded therapy concluded that there are insufficient randomized trials to assess the clinical risk of breast cancer, endometrial cancer or cardiovascular disease. Absence of evidence is not evidence of absence of risk.27
- National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A… Washington, DC: National Academies Press; 2020.DOI
- Liu Y, Yuan Y, Day AJ, Zhang W, John P, Ng DJ, Banov D. Safety and efficacy of compounded bioidentical hormone therapy (cBHT)… Menopause. 2022.
- FDA-approved prescribing information, PROMETRIUM (progesterone, USP) Capsules, Acertis Pharmaceuticals LLC, label version 4 published July 2026.DailyMed
- The Writing Group for the PEPI Trial Effects of hormone replacement… JAMA. 1996.
- Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium… Climacteric. 2000.
- Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and… Menopause. 2005.
- US Food and Drug Administration. Menopause. Consumer information on women's health topics, content current as of December 14, 2023.FDA
Do not use if you have
- A history of breast cancer or another estrogen-dependent cancer
- Unexplained vaginal bleeding
- A prior blood clot, stroke or heart attack
- An inherited clotting disorder
- Liver disease
- A known anaphylactic reaction, angioedema, or hypersensitivity to the product
- A known hypersensitivity to progesterone or to any of its ingredients
- Pregnancy
Serious risks
- An increased risk of endometrial cancer when estrogen is unopposed in a woman who still has a uterus
- Stroke, deep vein thrombosis and pulmonary embolism, along with gallbladder disease
- Probable dementia in women who begin therapy at 65 or older
- Breast cancer when estrogen and a progestogen are taken together over longer use
Commonly reported
- Breast tenderness
- Irregular vaginal bleeding or spotting
- Headache
- Low mood
- Irritation where the cream is applied
Because it is a cream
- Hormones applied to skin can transfer to another person through skin contact before the cream dries
- The specific issue with a combined cream is endometrial protection
- The National Academies review of compounded hormone therapy found no studies that could support conclusions about endometrial cancer risk for compounded estrogen or progesterone preparations
Reported effects follow the hormones involved. This is a compounded preparation, so it has not been reviewed by the FDA for safety, effectiveness, or quality, and estriol is not a component of any FDA-approved drug product. The approved labeling for estradiol is the best available guide to class risk. Whether progesterone delivered in a cream protects the uterine lining the way oral progesterone is prescribed to is a question your provider answers for your case rather than assumes. A licensed provider decides whether a combined preparation fits, or whether separate components serve you better, and a licensed 503A pharmacy prepares it only after that decision.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
For a patient with a uterus, systemic estrogen generally requires a progestogen to protect the uterine lining. A combined compounded preparation can put both prescribed components in one format when a clinician determines an individualized formulation is appropriate. The ratio and route are not selected at checkout.
The risks of systemic hormone therapy, stated plainly: blood clots, stroke, and, with combined estrogen and progestogen use over time, an increased risk of breast cancer. Compounding does not remove or reduce these risks. Your provider reviews your personal risk factors before prescribing and revisits them through your ongoing care.
That is the right question to ask, and the honest answer is that it is your provider’s call to make for your case. Oral micronized progesterone has the strongest evidence for endometrial protection, and some providers prefer it even alongside a compounded estrogen cream. Your provider explains their reasoning and monitors your plan accordingly.